Ratings Orthofix Medical Inc.

Equities

OFIX

US68752M1080

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
14.64 ^USD	+1.04%		+7.65%	+8.61%

May. 09	Orthofix Medical Inc. Announces FDA 510(K) Clearance for the Rodeo Telescopic Nail	CI
May. 08	Roth MKM Upgrades Orthofix Medical to Buy From Neutral With $20 Price Target	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

Low profitability weakens the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
ORTHOFIX MEDICAL INC.	+8.61%	549M	C+
ABBOTT LABORATORIES	-4.84%	182B	C+
MEDTRONIC PLC	+0.56%	110B	C
BECTON, DICKINSON AND COMPANY	-3.35%	68.11B	A
DEXCOM, INC.	+2.39%	50.53B	B-
CENCORA, INC.	+9.36%	44.8B	B-
HOYA CORPORATION	+2.70%	40.7B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+24.51%	32.3B	B
WEST PHARMACEUTICAL SERVICES, INC.	+3.43%	26.53B	A-
ZIMMER BIOMET HOLDINGS, INC.	-0.32%	24.96B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes